Introduction {#S0001}
============

Since the beginning of its application, endovascular aortic repair (EVAR) has been considered for abdominal aortic aneurysms with suitable anatomy in higher risk patients only \[[@CIT0001]--[@CIT0005]\]. Thereafter, the promising results coming from single-center series extended the application of EVAR even in challenging cases \[[@CIT0006]--[@CIT0008]\].

Recently, the published long-term results of celebrated clinical trials have questioned the benefits of EVAR by reporting the high need of secondary interventions \[[@CIT0009], [@CIT0010]\]. Nevertheless, the same studies also confirmed low perioperative mortality and morbidity rates for EVAR, and low reintervention rates were observed for favorable anatomy. Most of the redo procedures were amenable to endovascular or minimally invasive treatments, with a lower negative impact on the long-term outcomes \[[@CIT0006], [@CIT0007], [@CIT0010], [@CIT0011]\].

Few contemporary studies have reported a comparison of late outcomes after either EVAR or conventional open repair (OPEN) of abdominal aortic aneurysms (AAA) \[[@CIT0001]--[@CIT0014]\]. The present study aimed to compare the clinical and technical outcomes between EVAR and conventional OPEN procedures.

Material and methods {#S0002}
====================

This was a prospective, observational, non-randomized, per protocol study designed to compare long-term results of EVAR vs. OPEN repair for abdominal aortic aneurysms.

Patient population {#S20003}
------------------

Patients who had undergone repair of an infrarenal ruptured AAA were included. Inclusion criteria were AAA ≥ 55 mm for male (50 mm for female) patients or diameter increase of ≥ 5 mm on two consecutive follow-up examinations. Symptomatic and ruptured AAA were included to have "real life" analyses for either OPEN or EVAR treatments. Conversely, subjects with redo aortic surgery or suprarenal/thoraco-abdominal aortic reconstruction were excluded. The study protocol was in compliance with the local Institutional Review Board and received full approval. All patients gave their consent to participate.

Patient management {#S20004}
------------------

Patients were selected as possible candidates for EVAR on the basis of contrast enhanced computed tomography (CT) with 3-mm to 5-mm cuts. Three-dimensional vascular reconstructions were performed when possible. Risk factors and morphologic features were classified according to the Society for Vascular Surgery/International Society for Cardiovascular Surgery reporting standards \[[@CIT0015], [@CIT0016]\]. Vascular surgeons and interventional radiologists were responsible for selecting OPEN versus EVAR for each patient: CR was always offered in patients with unsuitable anatomy; however, anatomic criteria for exclusion from EVAR were less stringent in patients at high risk, but in the first phase of the endovascular experience, EVAR was also offered to low-risk patients with suitable anatomy who preferred this type of intervention. All procedures were performed in the theater, fully equipped for all types of endovascular procedures; radiology imaging was performed with a high-quality portable C-arm (BV300^®^-Siemens; Munich-GER) fluoroscopic unit with digital imaging and road mapping capability. Conventional repair (OPEN group) was performed under general anesthesia, while EVAR procedures were performed under general anesthesia with oro-tracheal intubation (in the great majority of cases) or under epidural anesthesia or local anesthesia in the remaining patients. Open common femoral artery exposure by means of a small groin incision was used for the endograft (EG) access. A tube graft was used in 109 (79%) CR cases; generally, a knitted Dacron (*n* = 136, 99%) graft (Uni-graft^®^, Carbograft^®^; Bard Inc.-Murray Hill-NJ; USA) was implanted. Endograft configuration was bifurcated infrarenal in 124 (71.7%) cases, bifurcated transrenal in 30 (17.3%), aorto-uni-iliac in 18 (10.4%), and tube transrenal in 1 (0.6%). Manufacturers were as follows: Excluder^®^ (W.L. Gore & Associates; Flagstaff, AZ; USA) for all infrarenal EG, transrenal EG used were Zenith^®^ (Cook Inc.; Bloomington, IN; USA) in 42, Talent^®^ (Medtronic; Santa Rosa, CA; USA) in 6, Lifepath^®^ (Edwards; Irvine, CA; USA) in 4, Powerlink^®^ (Endologix; Irvine, CA; USA) in 3, and Fortron^®^ (Cordis Corp; Miami Lakes, FL; USA) in 1 case.

The postoperative surveillance protocol consisted of clinical, duplex ultrasound scanning at 1, 6, 12 months, and then on a yearly basis after CR. Computed tomography scans were performed only when graft-related complications were suspected. Patients who underwent EVAR were scheduled for routine clinical follow-up with CT scheduled at 1, 6 and 12 months, then yearly.

Outcome measures and definitions {#S20005}
--------------------------------

Primary outcomes included operative (≤ 30 days) mortality, AAA rupture, aneurysm-related mortality, surgical conversion to open conventional repair, and late survival. Aneurysm-related mortality (ARM) was defined as death from any cause within 30 days of the primary EVAR procedure, death within 30 days of any secondary reintervention or surgical conversion, or any death due to aneurysm rupture or device complication. In addition, secondary outcomes including data related to endoleak and EG patency were examined. Finally, the frequency of secondary reintervention was determined, as well as the time, method, and success of such re-interventions. Outcome criteria were defined according to the Ad Hoc Committee for Standardized Reporting Practices in Vascular Surgery of the Society for Vascular Surgery/American Association for Vascular Surgery (SVS/AAVS) \[[@CIT0015], [@CIT0016]\].

Statistical analysis {#S20006}
--------------------

Clinical data were prospectively recorded and tabulated with Microsoft Excel (Microsoft^®^ Corp, Redmond, Washington). Data were described as mean and standard deviation (SD) or median and interquartile range (25^th^ to 75^th^ percentile) for continuous variables and as number and/or percent for the categorical ones. Continuous variables were tested for normal distribution by the Kolmogorov-Smirnov test and compared between groups with unpaired Student *t* test for normally distributed values; otherwise, the Mann-Whitney *U* test was used. In the case of dichotomous variables, group differences were examined by Pearson χ^2^ or Fisher exact tests as appropriate. In an attempt to control for selection bias related to the procedures of AAA repair, a propensity score analysis was developed, assuming the OPEN group as the treatment one. A multivariable logistic regression analysis to calculate propensity score was applied. The propensity score was based on significant demographic and clinical variables in the univariate analysis. The variables included in the final model were age, gender, emergency/elective status, prior vascular surgery (reoperation), history of coronary artery disease, congestive heart failure, concomitant heart valvulopathy, cardiac arrhythmias, hypertension, diabetes mellitus, dyslipidemia, chronic obstructive pulmonary disease, history of cerebrovascular accident, chronic renal failure, aneurysm presentation, SVS score, and finally the aneurysm diameter. This process generated a propensity score between 0 and 1 and patients receiving EVAR procedures were matched 1: 1 to those undergoing conventional repair (OPEN group), using the Rosenbaum optimal matching algorithm \[[@CIT0017]\]. This approach minimizes the overall distance between observations and was conducted using Mahalanobis distance within propensity score calipers (no matches outside the calipers) \[[@CIT0017]\]. After the propensity score match was performed, we assessed differences between the two groups as above. Absolute standardized differences were estimated to evaluate the prematch imbalance and postmatch balance \[[@CIT0017]\]. An absolute standardized difference of 0% indicates no residual bias and differences \< 10% are considered inconsequential \[[@CIT0018]\].

Univariate and multivariate approaches (logistic and Cox regression analyses) were then performed to identify variables potentially associated with study end-points. Regarding multivariate analyses, a stepwise approach was used and confirmed by backward and forward methods. The models were built using variables that demonstrated a *p* value \< 0.20 in univariate mode. The significance within the models was evaluated with the Wald test. The strength of the association of variables with hospital mortality was estimated by calculating the odds ratio (OR) and 95% confidence intervals (CIs). The model was calibrated by the Hosmer-Lemeshow goodness-of-fit test, as well as residual diagnostics (deviance and dfBetas); model discrimination was evaluated by using the area under the receiver operating characteristic (ROC) curve. For late outcomes (log-term mortality and morbidity, freedom from reinterventions and complications), hazard ratios (HRs) were generated by a Cox regression analysis. Late outcomes were also assessed using Kaplan-Meier life-table analysis and the Mantel-Cox log-rank test was applied when comparing subgroups. All tests were 2 sided, and a value of *p* ≤ 0.05 was considered statistically significant. Statistical analysis was computed using SPSS, release 19.0 for Windows (SPSS^®^ Inc; Chicago, IL; USA) and NCSS 2007, release 7.1 (Kaysville, UT; USA).

Results {#S0003}
=======

Patient demographics {#S20008}
--------------------

Between January 2000 and December 2005, a total of 311 patients having EVAR or OPEN repair of infrarenal AAA treated in our tertiary care university hospital were identified and formed the study group. Among the 311 enrolled patients, repair was performed on an emergency basis in 70 (23%) cases. The study cohort contained 279 (90%) males; mean age was 71.7 ±8.9 years (range: 48--96). OPEN repair was performed in 138 (44%) cases, EVAR in 173 (56%). The propensity score-based greedy-matching algorithm matched 138 patients for each group ([Table I](#T0001){ref-type="table"}). Postmatch absolute standardized differences for all measured covariates were \< 10% (most were \< 5%), suggesting substantial covariate balance across groups ([Figure 1](#F0001){ref-type="fig"}). Both groups appeared comparable in pre- and perioperative characteristics and risk factors; mean SVS score was not statistically significant (3 (25^th^ to 75^th^ percentile, 2 to 5) vs. 3 (25^th^ to 75^th^ percentile, 2 to 4), *p* = 0.487).

![Baseline risk factors and variables: Absolute standardized differences between OPEN (conventional surgical repair) and EVAR (endovascular aortic repair) for abdominal aortic aneurysm, in the aggregate (black open diamonds) and in the propensity matched cohorts (gray closed diamonds)](AMS-10-22708-g001){#F0001}

###### 

Demographic and clinical data with reference to procedure group

  Variable[\*](#TF0001){ref-type="table-fn"}   Prematch      Postmatch                               
  -------------------------------------------- ------------- ----------- ------------- ------------- -------
  Age \[years\]                                72.2 ±8.5     0.302       71.5 ±8.6     71.2 ±9.3     0.742
  Males                                        157 (90.8)    0.499       125 (90.6)    122 (88.4)    0.556
  Emergency                                    44 (25.4)     0.167       27 (19.6)     26 (18.8)     0.879
  Prior surgery                                25 (14.5)     0.119       15 (10.9)     12 (8.7)      0.543
  CAD                                          60 (34.7)     0.178       40 (29.0)     38 (27.5)     0.789
  Arrhythmia                                   41 (23.7)     0.091       25 (18.1)     22 (15.9)     0.631
  CHF                                          15 (8.7)      0.035       6 (4.3)       4 (2.9)       0.749
  Heart valvulopathy                           9 (5.2)       0.621       9 (6.5)                     
  Hypertension                                 138 (79.8)    0.353       105 (76.1)    104 (75.4)    0.888
  Diabetes                                     17 (9.8)      0.296       11 (8.0)      9 (6.5)       0.642
  Dyslipidemia                                 54 (31.2)     0.480       43 (31.2)     38 (27.5)     0.509
  COPD                                         22 (12.7)     0.070       12 (8.7)      9 (6.5)       0.496
  CVA                                          21 (12.1)     0.728       18 (13.0)     15 (10.9)     0.578
  CRF                                          16 (9.2)      0.094       6 (4.3)       6 (4.3)       0.999
  SVS Score (*n*)                              4 (3--5)      0.035       3 (2--5)      3 (2--4)      0.487
  Presentation:                                              0.088                                   0.331
   Asymptomatic                                134 (77.5)                112 (81.2)    110 (79.7)    
   Symptomatic                                 15 (8.7)                  8 (5.8)       4 (2.9)       
   Ruptured                                    24 (13.9)                 18 (13.0)     24 (17.4)     
   Aneurysm diameter \[mm\]                    73 (66--78)   0.001       50 (47--60)   50 (40--60)   0.322

For continuous variables, mean ± SD or median (25^th^ to 75^th^ percentile); for categorical variables, number (percent)

For continuous variables, Student t test or the Mann-Whitney U test; for categorical ones, *χ*^2^ or Fisher exact test

EVAR compared with OPEN procedures in whole patient population (prematch comparison); CAD -- coronary artery disease, CHF -- chronic heart failure, COPD -- chronic obstructive pulmonary disease, CRF -- chronic renal failure, CVA -- cerebrovascular accidents, SVS -- Society for Vascular Surgery

In-hospital outcome {#S20009}
-------------------

The primary technical success (successful deployment with no complication requiring adjunctive procedures) rate was 99.6% (275/276); conversion from EVAR to OPEN repair was never needed. Mean operation time was longer in the OPEN group (150 min (25^th^ to 75^th^ percentile, 120 to 196 min) vs. 120 min (25^th^ to 75^th^ percentile, 90 to 142 min), *p \<* 0.001). Adjunctive procedures were performed similarly (17% vs. 20%, *p* = 0.639).

Postoperatively, the OPEN group had a higher complication rate in terms of respiratory failure occurrence (12% vs. 4%, *p* \< 0.026) and transfusion requirement (46% vs. 19%, *p* \< 0.001) ([Table II](#T0002){ref-type="table"}). The intensive care unit (ICU) admission rate (27% vs. 7%, *p* \< 0.001) was higher in the OPEN group; a longer hospitalization (7 days (25^th^ to 75^th^ percentile, 8 to 12 days) vs. 5 days (25^th^ to 75^th^ percentile, 4 to 7 days), *p \<* 0.001) was observed in the OPEN group.

###### 

Postoperative data with reference to procedure group

  Variable[\*](#TF0004){ref-type="table-fn"}   EVAR (*n* = 138)   OPEN (*n* = 138)   *P* [†](#TF0005){ref-type="table-fn"}
  -------------------------------------------- ------------------ ------------------ ---------------------------------------
  Operative:                                                                         
   Adjunctive procedure                        27 (19.6)          23 (16.7)          0.532
   Operation time \[min\]                      120 (90--142)      150 (120--196)     \< 0.001
  Postoperative:                                                                     
    Reoperation:                                                                     0.112
    Endovascular                               2 (1.4)            3 (2.2)            
    Conventional surgery                       5 (3.6)            11 (8.0)           
   Transfusion:                                26 (18.8)          64 (46.4)          \< 0.001
    RBC units (*n*)                            0.7 ±1.7           2.0 ±2.4           \< 0.001
    FFP units (*n*)                            0.7 ±1.7           1.9 ±2.4           \< 0.001
   Complications:                              21 (15.2)          32 (23.2)          0.093
    Cardiac                                    5 (3.6)            11 (8.0)           0.197
    Respiratory                                6 (4.3)            16 (11.6)          0.026
    Renal                                      5 (3.6)            3 (2.2)            0.502
    Procedure related                          9 (6.5)            13 (9.4)           0.374
   ICU admission                               9 (6.5)            37 (26.8)          \< 0.001
   LOS (days)                                  5 (4--7)           7 (8--12)          \< 0.001
   Hospital mortality                          8 (5.8)            23 (16.7)          0.004

For continuous variables, mean ± SD or median (25^th^ to 75^th^ percentile); for categorical variables, number (percent);

For continuous variables, Student t test or the Mann-Whitney U test; for categorical variables, Pearson\'s *χ* ^2^ or Fisher exact test; ICU -- intensive care unit, LOS -- length of hospitalization, RBC -- red blood cells, FFP -- fresh frozen plasma

The overall in-hospital mortality in these two groups was 11% (31/276 patients). In-hospital mortality was higher in older (75.9 ±9.5 vs. 70.8 ±8.7 years, *p* = 0.006) patients; they also had more co-morbidities (SVS score: 4.2 ±1.9 vs. 3.3 ±1.6, *p* = 0.020). Hospital mortality was higher in the OPEN group (17% vs. 6%, *p* = 0.004). Although this difference persisted between groups in patients aged ≥ 75 years (23% vs. 7%, *p* = 0.033), no differences were noted for patients aged \< 75 years (12% vs. 5%, *p* = 0.100). In multivariable analysis, predictors of hospital mortality were clinical presentations of AAA, chronic heart failure and OPEN procedure (*p* ≤ 0.001, *p* = 0.003, and *p* = 0.009, respectively; [Table III](#T0003){ref-type="table"}). The Hosmer-Lemeshow goodness-of-fit test was not significant for lack of fit (χ^2^ \[3 df\] = 1.97, *p* = 0.602), indicating that there was no statistically significant departure from a perfect fit. Similarly, the ROC analysis (AUC of 0.96) revealed excellent discrimination for the multivariable model.

###### 

Independent predictors for hospital mortality, late mortality and reinterventions

  Variable                    Wald χ^2^   *P*        OR[\*](#TF0006){ref-type="table-fn"}   95% CI
  --------------------------- ----------- ---------- -------------------------------------- --------------
  Hospital mortality                                                                        
  Clinical presentation^†^:   31.98       \< 0.001                                          
    AAA                       8.16        0.004      17.93                                  2.48--129.83
    Ruptured AAA              22.03       \< 0.001   14.57                                  4.76--44.62
   CHF                        8.78        0.003      31.87                                  3.23--314.58
   OPEN procedure             6.82        0.009      4.86                                   1.48--15.93
  Late mortality:                                                                           
   Age                        37.47       \< 0.001   1.09                                   1.06--1.12
   CHF                        22.82       \< 0.001   7.34                                   3.24--16.61
   ICU admission              5.80        0.016      2.04                                   1.14--3.64
   Transfusion                4.62        0.032      1.64                                   1.04--2.57
  Late reintervention:                                                                      
   Aneurysm diameter          9.64        0.002      1.03                                   1.01--1.05
   EVAR procedure             8.48        0.004      2.95                                   1.43--6.12
   History of CVA             8.09        0.004      2.90                                   1.39--6.05

For hospital mortality multivariable logistic regression; for late mortality and reinterventions, multivariable Cox analysis; AAA -- abdominal aortic aneurysm, CI -- confidence interval, CHF -- chronic heart failure, CVA -- cerebrovascular accident, EVAR -- endovascular repair for AAA, ICU -- intensive care unit, HR -- hazard ratio, OR -- odds ratio

Late outcome {#S20010}
------------

Two-hundred forty-five patients were discharged alive; two (0.8%) patients were lost to follow-up. The remaining 243 patients were followed up for a median of 70 months (25^th^ to 75^th^ percentile, 24 to 101); out of this group, 100 died. Cause of death was AAA-related in 7 cases: specifically, 6 patients (OPEN *n* = 2 vs. EVAR *n* = 4; *p* = 0.686) died because of a secondary rupture and 1 (OPEN group) died of complications following secondary intervention for thrombosis of the EG. Other causes of death were cerebrovascular accidents (*n* = 46, 19%), cancer (*n* = 27, 11%), and other causes (*n* = 20, 8%).

Long-term mortality was similar in the groups (*p* = 0.465): actuarial survival estimates at 1, 5 and 10 years were 93%, 74%, 49% for OPEN procedures, and 89%, 69%, 59% for EVAR. A significant difference was observed in younger (\< 75 years) patients only (*p* \< 0.044). Differences were not noted for patients aged ≥ 75 years (*p* = 0.216) ([Figure 2](#F0002){ref-type="fig"}). According to the multivariable Cox analysis, age (HR = 1.09; 95% CI: 1.06--1.12), chronic heart failure (HR = 7.34; 95% CI: 3.24--16.61), ICU admission (HR = 2.04; 95% CI: 1.14--3.64) and postoperative transfusions (HR = 1.64; 95% CI: 1.04--2.57) were independent predictors for late mortality ([Table III](#T0003){ref-type="table"}).

![Kaplan-Meier actuarial survival curves for patients undergoing conventional surgical repair (OPEN) and endovascular repair (EVAR) of abdominal aortic aneurysm. **A** -- All patients considered. **B** -- Panel reported differences with reference to age groups](AMS-10-22708-g002){#F0002}

Late complications occurred in 60 (25%) patients: 53 (22%) were procedure-related, whereas 7 (3%) were ascribed to other causes. The late complication rate was significantly higher in EVAR patients (*p* \< 0.001). In particular, the EVAR group experienced a total of 42 procedure-related complications; endoleaks were detected in 23 subjects (type 1 *n* = 10, type 2 *n* = 11, and type 3 *n* = 2). In the OPEN group, 11 patients had procedure-related complications: proximal anastomotic pseudoaneurysms (*n* = 7), rupture of secondary aneurysm location (*n* = 3), grade 2 wound infections following the Samson \[[@CIT0017]\] classification (*n* = 2), and graft thrombosis (*n* = 1). Freedom from late complication rates at 1, 5 and 10 years were 96%, 92%, 86% for OPEN repair, and 84%, 70%, 64% for EVAR ([Figure 3](#F0003){ref-type="fig"}).

![Actuarial freedom from complications and reinterventions between patients undergoing conventional surgical repair (OPEN) and endovascular repair (EVAR) of abdominal aortic aneurysm (EVAR)](AMS-10-22708-g003){#F0003}

Over the study period, 38 re-interventions occurred after a median postoperative interval of 14 months (25^th^ to 75^th^ percentile, 3 to 41). Ten (26%) patients required multiple procedures. Emergent re-intervention was performed in 11 (29%) cases. Re-interventions were endovascular in 23 patients and surgical in 15. The re-intervention rate was significantly worse in the EVAR group (*p* = 0.002). Freedom from re-intervention rates at 1, 5 and 10 years were 97%, 95%, and 91% for OPEN repair, and 89%, 81%, and 77% for EVAR ([Figure 3](#F0003){ref-type="fig"}). In the multivariable Cox analysis, independent predictors for re-intervention were the native aneurysm diameter (HR = 1.03; 95% CI: 1.01--1.05), EVAR procedure (HR = 2.95; 95% CI: 1.43--6.12) and a preoperative history of cerebrovascular accidents (HR = 2.90; 95% CI: 1.39--6.05) ([Table III](#T0003){ref-type="table"}).

Discussion {#S0004}
==========

The main findings of our study were the confirmation of better overall outcomes for EVAR in the early postoperative period; and in the long-term period, the similar results of mortality and the higher re-intervention rate required after EVAR. These results are consistent with other previous reported papers; nevertheless, our study had the merit of having used an algorithm to obtain two well-matched groups of patients to mitigate potential confounding factors and bias \[[@CIT0008], [@CIT0012], [@CIT0013], [@CIT0019]\].

Previous single-center or randomized clinical trials have shown better efficacy and safety of EVAR in the early postoperative period \[[@CIT0003]--[@CIT0005], [@CIT0007], [@CIT0010]\]. Few data are available analyzing the long-term outcomes: the results of the EVAR-1 trial highlighted that AAA-related mortality was reduced during the early years after EVAR, but this benefit was completely lost over a median follow-up period of 6 years \[[@CIT0010]\]. Our study was not intended as a randomized clinical trial, but we mitigated the potential bias stemming from the observational nature of our analysis: when comparing the results of the EVAR-1 trial with the data of our experience, we observe a significant difference in mortality. Survival was not significantly different between the EVAR and OPEN groups in the early postoperative period as well as in the long-term: these data are more surprising if we take into account that we intentionally included urgent repairs for ruptured AAA in the analyses.

Another main finding of the present study is the identification of independent predictors of late mortality. In a previous study on EVAR for high-risk patients, we identified several parameters that adversely affected long-term mortality rate, such as age, ASA score, gender, and native aneurysm diameter \[[@CIT0011]\]. Indubitably, age is an important issue in all surgical interventions. Sicard *et al*. \[[@CIT0012]\] stated that EVAR can be considered a safe alternative to OPEN repair in octogenarians due to a dramatic reduction in complication and mortality rates. Our experience is in consonance with these data: although we used a different, lowered cut-off (75 years) we noted an advantageous trend to better survival in the early period, as well as non-inferior survival also in the longer run for the older patients. In their report on the first decade of EVAR, Brewster *et al*. \[[@CIT0020]\] reported similar long-term outcomes, and suggested EVAR as a reasonable alternative to conventional OPEN repair in a broad range of patients with suitable anatomy, including younger and better-risk individuals \[[@CIT0020]\].

Diameter has been identified a significant predictive parameter of long-term mortality. Zarins *et al*. \[[@CIT0021]\] found that patients with large aneurysms (≥ 6 cm) needed more re-interventions during a 5-year follow-up, and had a significantly shorter life expectancy than patients with smaller AAAs. Ouriel *et al*. \[[@CIT0022]\] reported excellent results with EVAR for small AAAs: their mid-term outcomes of large AAAs were associated with increased rates of aneurysm-related death, unrelated death, and rupture. More recently, the CESAR trial showed three important results: no clear advantage between early or delayed EVAR for small AAAs within 36 months of follow-up; most of the small AAAs under surveillance grew and required repair; and notably, 15% of the AAAs lost EVAR suitability \[[@CIT0023]\]. Our data partly support these results: diameter was noted to be a strong independent marker of long-term mortality, probably because larger AAAs were seen more frequently in older and sicker patients.

The ultimate goal of EVAR procedures is aneurysm exclusion and prevention of rupture \[[@CIT0010]\]. Aneurysm-related mortality is one of the most cited outcomes in published papers. A review of 4291 patients from the EUROSTAR registry by Peppelenbosch *et al*. \[[@CIT0024]\] identified 34 (0.8%) late ruptures after EVAR with a mortality rate of 64%. In a recent analysis, Wyss *et al*. \[[@CIT0025]\] noted 27 ruptures only across the EVAR experience in both EVAR trials 1 and 2 \[[@CIT0009], [@CIT0010], [@CIT0025], [@CIT0026]\]. The paper concluded that this was a low percentage, but also suggested that this small number of ruptures would seem to explain the convergence in aneurysm-related mortality in the recently reported long-term analysis of the EVAR-1 trial \[[@CIT0010]\]. In our study, AAA-related mortality was 2.9% and rupture was experienced in each group without a significant difference between the groups. It has been supposed that the type of device could have been potentially related to late ruptures \[[@CIT0008], [@CIT0018], [@CIT0027]\]. Wibmer *et al*. \[[@CIT0028]\] reported 10-year mortality after EVAR of 60% with 4.6% AAA-related death, two-fold higher than in EVAR-1 \[[@CIT0010]\]. The authors concluded that the probability of death from late AAA rupture is much lower than the risk of death from other causes during the same period, even in patients treated with first-generation EGs \[[@CIT0028]\]. The experience of Brewster *et al*. \[[@CIT0020]\] with new generation devices confirmed these observations: they obtained a low rate (1%) of late rupture with freedom from AAA-related death of 97% at 1 year, 96% at 5 years, and 93% at 9 years.

The re-intervention rate after EVAR has been confirmed to be high in several studies; most alarmingly, this trend was associated with newer devices too \[[@CIT0008], [@CIT0011], [@CIT0029], [@CIT0030]\]. Becquemin *et al*. \[[@CIT0031]\] reported a 27% re-intervention rate at a median follow-up of 18 months, and Sampram *et al*. \[[@CIT0028]\] estimated a rate of re-intervention of 35% at 3 years. Endovascular aortic repair patients faced re-interventions more frequently than those operated on conventionally, with a need of redo of 11% within the first year and 19% at 5 years. This consistent need for re-intervention after EVAR, coupled with adverse outcomes reported in some papers, led some authors to question the broad application of EVAR \[[@CIT0010], [@CIT0032], [@CIT0033]\]. This observation deserves some comments. We should take into account that patients who underwent EVAR probably had a more vigilant follow-up program, particularly in the early phase of the endovascular era. More frequently surveillance was performed at the same center, contrary to what would happen in the case of OPEN repair, therefore potentially underestimating the real incidence of re-intervention. In addition, one should take into account the tendency of some physicians to be more apt to intervene: this could have potentially influenced the higher number of secondary procedures \[[@CIT0022], [@CIT0027]\]. However, only the long-term analysis of the EVAR-1 trial has ascertained an increased rate of re-intervention for EVAR \[[@CIT0010]\]. It is important to emphasize that also in our experience most of the secondary procedures in the EVAR group were performed endovascularly, and that they did not influence long-term survival. Similarly, in the series of Conrad *et al*. \[[@CIT0034]\] freedom from aneurysm-related death remained high, as did the overall survival in the redo patients.

The literature is rich in papers quoting re-interventions; unfortunately, not always do they clarify the role of the diameter of the AAA as a predisposing factor for re-intervention \[[@CIT0006], [@CIT0007], [@CIT0011], [@CIT0021]--[@CIT0024]\]. In our study, a diameter of more than 55 mm correlated with increased need for re-intervention. This result has been confirmed in other extensive studies: Sampram *et al*. \[[@CIT0030]\] found a strong relationship between AAA size and the need for re-intervention, and strongly suggested that unfavorable anatomy, which the literature has demonstrated to have often been associated with larger aneurysm, could be a predictor of re-intervention \[[@CIT0030]\]. Boult *et al*. \[[@CIT0007]\] found that larger sac size was predictive of the late development of endoleaks requiring reoperation. Our results seem to confirm these data: we found that the maximum AAA diameter could be significantly correlated with higher incidence of unfavorable anatomy, and the combination of a large AAA with hostile anatomy could be significantly associated with increased incidence of re-intervention, and is a useful parameter for better stratification of the risk of re-intervention.

The EVAR-1 trial data showed that the immediate benefits of EVAR are lost in the follow-up along with a greater number of complications, need for re-intervention and consequently an increase in-hospital costs \[[@CIT0010]\]. In our study we did not perform a cost analysis; nevertheless, re-interventions did not influence negatively the overall mortality rate of EVAR, and we observed a significant reduction of the operation time for EVAR, with an increased ICU admission rate and postoperative transfusion requirement following OPEN repair. Noll *et al*. \[[@CIT0035]\] performed a cost analysis comparison of EVAR vs. OPEN repairs, with an additional analysis of the costs for the re-interventions. The authors found a higher total cost of 25% for EVAR; they identified many variables that were associated with increased costs, but the most powerful were the ICU stay and length of hospitalization. These variables could be frequently affected by procedural and/or postoperative complications. Unquestionably, the initial cost of the prosthetic material is much higher in EVAR; however, in our experience EVAR had favorable results in terms of duration of intervention, overall length of hospitalization, as well as in terms of blood transfusions and postoperative ICU resource utilization. It is possible that these data can drastically reduce or obliterate the different economic margin with OPEN repair. These same data are of much interest when paired with those regarding the survival of older patients \[[@CIT0033], [@CIT0036]\]. Indeed, EVAR had more benefits for older patients, which seemed to be maintained in the long term too. The endovascular approach would thus appear to be the treatment of choice for patients older than 75 years.

Our study has several limitations \[[@CIT0005], [@CIT0023], [@CIT0030]\]. It is a single-center observational investigation; selection bias may have been present, although we attempted to mitigate it using a propensity score analysis. However, this process allowed us to identify two (EVAR vs. OPEN) groups of patients, well matched in terms of demographic and morphological characteristics: our experience is a faithful mirror of "real life", no less deserving of importance in terms of "daily" clinical practice.

In conclusion, our study confirms the excellent results of EVAR in terms of safety and significant reduction of early mortality. Age has been confirmed as a significant predictor: patients above 75 years would seem to benefit from EVAR not only in the immediate postoperative period but even in long-term follow-up. Congestive heart disease has been identified as a further marker of long-term mortality: therefore, evaluation of a dedicated predictive score could be of significant utility in identifying those patients at higher operative risk, so that also EVAR could not be justified under very low survival rates in these patients. The diameter of the aneurysm has been the most influential predictor for reoperation: this rate is not irrelevant (19%) in our experience but most of these "redo" procedures were performed endovascularly and were not significant in terms of mortality.
